Matrix metalloproteinase-2 is involved in myelination of dorsal root ganglia neurons

Helmar C Lehmann1, Angelika Köhne, Fabian Bernal

  • 1Department of Neurology, Heinrich-Heine-University, Moorenstrasse, Düsseldorf, Germany. helmar.lehmann@uni-duesseldorf.de

Glia
|September 25, 2008
PubMed

Insights

Matrix metalloproteinases-2 (MMP-2) plays a key role in peripheral nervous system myelination. Inhibiting MMP-2 disrupts myelin formation, suggesting it

Area of Science:

  • Neuroscience
  • Biochemistry
  • Cell Biology

Background:

  • Matrix metalloproteinases (MMPs) are enzymes degrading extracellular matrix.
  • MMPs are implicated in tissue damage and repair, including nerve regeneration.
  • The role of MMPs in peripheral nervous system (PNS) myelination is not well understood.

Purpose of the Study:

  • To investigate the role of MMP-2 (gelatinase A) in PNS myelination.
  • To determine if MMP-2 activity influences myelin formation and integrity.
  • To explore MMP-2's relevance in demyelinating diseases.

Main Methods:

  • Utilized a co-culture model of Schwann cells and dorsal root ganglia neurons.
  • Assessed MMP-2 expression via immunocytochemistry, zymography, and ELISA.
  • Investigated effects of MMP-2 inhibition on myelination.
  • Analyzed MMP-2 levels in cerebrospinal fluid (CSF) and nerve biopsies from patients.

Main Results:

  • MMP-2 expression positively correlated with the degree of myelination in vitro.
  • Chemical inhibition of MMP-2 resulted in incomplete and abnormal myelin formation.
  • Elevated MMP-2 was detected in CSF of Guillain-Barré syndrome patients and in CSF/nerve biopsies from chronic inflammatory demyelinating polyneuropathy patients.

Conclusions:

  • MMP-2 plays a significant, previously unrecognized role in PNS myelination.
  • MMP-2 activity is crucial for proper myelin formation and maintenance.
  • Targeting MMP-2 activity may offer therapeutic potential for demyelinating PNS diseases.